Page last updated: 2024-08-23

1-deoxynojirimycin and Metabolic Syndrome

1-deoxynojirimycin has been researched along with Metabolic Syndrome in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aerts, JM; Aten, J; Bietrix, FM; Bijl, N; Boot, RG; Dekker, N; Groen, AK; Groener, J; Langeveld, M; Lombardo, E; Ottenhoff, R; Overkleeft, HS; Serlie, M; van Eijk, M; van Roomen, C; Wennekes, T	1
Higa, M; Masuzaki, H; Sata, M; Shimabukuro, M; Yamakawa, K	1

Reviews

1 review(s) available for 1-deoxynojirimycin and Metabolic Syndrome

Article	Year
Glycosphingolipids and insulin resistance. Advances in experimental medicine and biology, 2011, Volume: 721 Topics: 1-Deoxynojirimycin; Adamantane; Animals; Cardiovascular Diseases; Ceramides; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Fatty Acids; Fatty Liver; Gaucher Disease; Glucosyltransferases; Glycosphingolipids; Humans; Insulin Resistance; Metabolic Syndrome; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Pyrrolidines; Receptor, Insulin; Signal Transduction	2011

Article

Year

Glycosphingolipids and insulin resistance.

Advances in experimental medicine and biology, 2011, Volume: 721

Topics: 1-Deoxynojirimycin; Adamantane; Animals; Cardiovascular Diseases; Ceramides; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Fatty Acids; Fatty Liver; Gaucher Disease; Glucosyltransferases; Glycosphingolipids; Humans; Insulin Resistance; Metabolic Syndrome; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Pyrrolidines; Receptor, Insulin; Signal Transduction

2011

Trials

1 trial(s) available for 1-deoxynojirimycin and Metabolic Syndrome

Article	Year
Miglitol, α-glycosidase inhibitor, reduces visceral fat accumulation and cardiovascular risk factors in subjects with the metabolic syndrome: a randomized comparable study. International journal of cardiology, 2013, Sep-01, Volume: 167, Issue:5 Topics: 1-Deoxynojirimycin; Adult; alpha-Glucosidases; Cardiovascular Diseases; Female; Glycoside Hydrolase Inhibitors; Humans; Intra-Abdominal Fat; Male; Metabolic Syndrome; Middle Aged; Obesity; Risk Factors; Risk Reduction Behavior	2013

Article

Year

Miglitol, α-glycosidase inhibitor, reduces visceral fat accumulation and cardiovascular risk factors in subjects with the metabolic syndrome: a randomized comparable study.

International journal of cardiology, 2013, Sep-01, Volume: 167, Issue:5

Topics: 1-Deoxynojirimycin; Adult; alpha-Glucosidases; Cardiovascular Diseases; Female; Glycoside Hydrolase Inhibitors; Humans; Intra-Abdominal Fat; Male; Metabolic Syndrome; Middle Aged; Obesity; Risk Factors; Risk Reduction Behavior

2013